Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Completed · Phase 2 · NCT04116437
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
At a glance
- Research payments reported, 2025
- $5.5M
- U.S. investigators named
- 25
- Sites paid
- 22
- Planned or actual enrollment
- 96
About the trial
- Sponsor
- BeiGene
- Tested
- Zanubrutinib (drug)
- Dates
- Started 2019-10-15; completion 2026-01-09
- Results posted
- Not yet
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
From ClinicalTrials.gov, last updated 2026-01-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $5.5M in research payments for this study in 2025 (352 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sudhir Manda, MD Hematology & Oncology · Tucson, AZ
- John M. Burke, MD Hematology & Oncology · Aurora, CO
- Jamal G. Misleh, MD Hematology & Oncology · Newark, DE
- Jennifer L. Cultrera, M.D. Medical Oncology · Lady Lake, FL
- Santosh M. Nair, MD Hematology & Oncology · Orange City, FL
- Syed F. Zafar, M.D. Medical Oncology · Fort Myers, FL
- Subramanya Rao, M.D. Hematology & Oncology · Tinley Park, IL
- Ben Y. Zhang, MD Hematology & Oncology · Burnsville, MN
- Charles M. Farber, M.D, PHD Hematology & Oncology · Morristown, NJ
- Benjamin B. Freeman, M.D. Medical Oncology · Morristown, NJ
- Steven W. Papish, M.D. Hematology & Oncology · Morristown, NJ
- Edwin C. Kingsley, MD Hematology & Oncology · Las Vegas, NV
- Morton Coleman, MD Hematology & Oncology · New York, NY
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Joseph L. Potz, M.D. Hematology & Oncology · Horsham, PA
- Subhash C. Proothi, MD Hematology & Oncology · Fountain Hill, PA
- Ian W. Flinn, M.D. Hematology & Oncology · Nashville, TN
- Moshe Y. Levy, MD Medical Oncology · Dallas, TX
- Praveen K. Tumula, M.D Hematology & Oncology · Amarillo, TX
- Nurul A. Wahid, M.D. Hematology & Oncology · Mcallen, TX
- Habte A. Yimer IV, M.D. Hematology & Oncology · Tyler, TX
- Mitul Gandhi, M.D. Hematology & Oncology · Manassas, VA
- Gary L. Simmons, DO Hematology & Oncology · Norfolk, VA
- Arvind Chaudhry, MD Hematology & Oncology · Spokane, WA
- Mazyar Shadman, MD,MPH Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fred Hutchinson Cancer Center $1.8M
- Texas Oncology-Amarillo Cancer Center $939,659
- Summit Medical Group, P.a. $424,303
- Minnesota Oncolgy Hematology $356,320
- St. Luke's University Health Network $291,773
- Florida Cancer Specialists & Research Institute, LLC $251,520
- Medical Oncology Hematology Co $241,040
- Clinical Research Alliance, Inc. $168,497
- Morristown Medical Center $157,200
- Virginia Oncology Associates $157,200
- Healthcare Research Network III, LLC $104,800
- Florida Cancer Specialist (scri) - Fort Myers $104,200
- Tennessee Oncology $83,840
- Comprehensive Cancer Centers of Nevada - Central Valley $79,874
- Texas Oncology-Baylor Charles A. Sammons Cancer Center $70,752
- Investigational Product Center $62,880
- Arizona Oncology Associates $62,880
- Rocky Mountain Cancer Centers $52,400
- Medical Oncology Associates, Ps $52,400
- Alpha Clinical Research Centers LLC $22,070
- Morristown Medical Center, NJ $14,362
- The Sarah Cannon Research Institute, Tennessee Oncology, PLLC $3,182
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.